explore -WSS

explore

author：focus 2025-09-14 21:45:37 - browse：29354

In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.

The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.

A date for the meeting has not been set yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： A new crop of companies is reshaping the health data economy

WSS

Hey, doctors: Don't be no

New Alzheimer's drugs heat up race for early detection blood tests

Senate panel puts off hardest PBM reforms for another day

Biden, Billy Joel, Elton John lead tributes for Tony Bennett after singer's death at 96

Biden White House, tech companies launch new safeguards around emerging AI technology

Biogen says it will cut costs by $700 million, slash 1,000 jobs

hotspot

explore

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Why the advice to take all your antibiotics may be wrong

Activists slam private health insurers over coverage restrictions

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Affirmative action in medical school literally saved lives

Biden warns of ‘dark winter’ during final presidental debate

As demand for Covid shots wanes, Moderna seeks its next success

Roche’s Alnylam deal shows drug firms interested in heart drugs

Moonlake's readout produced a cash windfall. Risks remain

Family of Gilgo Beach murder suspect releases statement: 'Devastating time'

Wikipedia

Trump Organization, Michael Cohen agree to settle million

Senate panel puts off hardest PBM reforms for another day

Why the advice to take all your antibiotics may be wrong

Will the FTC rein in IQVIA's health data empire?

A former Republican legislative candidate has been charged for his role in the US Capitol riot

Washington Commanders' Dan Snyder ordered to pay NFL $60M following investigation

explore

knowledge

Wikipedia

leisure time